JournalsHub
.online
Find My Journal
GJ

Gerrit Jansen

Amsterdam University Medical Centers NL

ORCID 0000-0001-8190-8368
487
Publications
14,725
Citations
66
H-Index
229
i10-Index
1.78
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

487 total

High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial OA

Margot S F Roeten, J. van Meerloo, Suzanne N Van Dijk, Zinia W Kwidama, G. Jenkins - Haematologica, 2025
Cited by 0 Semantic Scholar

The role of alternative splicing in cancer: From oncogenesis to drug resistance PDF

Rocco Sciarrillo, Anna Wojtuszkiewicz, Yehuda G. Assaraf, Gerrit Jansen, Gertjan J.L. Kaspers et al. - Drug Resistance Updates, 2020
Cited by 311 OpenAlex

Drug resistance in pancreatic cancer: Impact of altered energy metabolism PDF

Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti - Critical Reviews in Oncology/Hematology, 2017
Cited by 270 OpenAlex

Proteasome inhibitors in acute leukemia

G. Jansen, Lesley F. V. Riethoff - Unknown Venue, 2014
Cited by 0 Semantic Scholar

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines OA

D. Niewerth, G. Kaspers, Y. Assaraf, J. van Meerloo, C J Kirk - Journal of Hematology & Oncology, 2014
Cited by 20 Semantic Scholar

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells OA

N. Franke, D. Niewerth, Y. Assaraf, J. van Meerloo, K. Vojtekova - Leukemia, 2012
Cited by 48 Semantic Scholar

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance PDF

Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots, Richard R. de Haas, Henk Dekker et al. - Clinical Cancer Research, 2011
Cited by 339 OpenAlex

Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein

Ruud Oerlemans, N. Franke, Yehuda G. Assaraf, Jacqueline Cloos, Ina van Zantwijk et al. - Blood, 2008
Cited by 446 OpenAlex

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Godefridus J. Peters, Harold H.J. Backus, SJ Freemantle, Baukelien van Triest, Giovanni Codacci-Pisanelli et al. - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
Cited by 430 OpenAlex

MRP3, an organic anion transporter able to transport anti-cancer drugs OA

Marcel Kool, Marcel van der Linden, Marcel de Haas, George L. Scheffer, J. Marleen L. de Vree et al. - Proceedings of the National Academy of Sciences, 1999
Cited by 649 OpenAlex

Research Topics

Acute Lymphoblastic Leukemia research (76) Folate and B Vitamins Research (72) Rheumatoid Arthritis Research and Therapies (56) Ubiquitin and proteasome pathways (47) Drug Transport and Resistance Mechanisms (46)

Affiliations

Boston University
US 2002 - 2002
Children's Oncology Group
CH 2025 - 2025
University of Toledo Medical Center
US 1999 - 1999
Merck & Co., Inc., Rahway, NJ, USA (United States)
US 1970 - 1964
Health Canada
CA 1980 - 1980

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now